Evidence map›Paper›PMID 24742347›Full record

ArticleRetrovirology2014

HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells.

Sami Kukkonen, Maria Del Pilar Martinez-Viedma, Nayoung Kim, Mariana Manrique, Anna Aldovini

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. The STAT Signaling Pathway in HIV-1 Infection: Roles and Dysregulation.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Genetic variation and function of the HIV-1 Tat protein.Medical microbiology and immunology · 2019
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Functional roles of HIV-1 Tat protein in the nucleus.Cellular and molecular life sciences : CMLS · 2016
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sami Kukkonen
Maria Del Pilar Martinez-Viedma
Nayoung Kim
Mariana Manrique
Anna AldoviniDepartment of Pediatrics, Harvard Medical School, Department of Medicine, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. anna.aldovini@childrens.harvard.edu.
Harvard University · US

Funding

Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotectionR01MH095671 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI ALDOVINI, ANNA, KOLSON, DENNIS LARRY · 2011 to 2015
$3.5M
NIMH NIH HHS R01 MH095671
6 · The paper itself

Abstract

backgroundWe have shown that HIV-1 Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters is key to IFN-stimulated genes (ISG) activation in immature dendritic cells and macrophages.

resultsWe evaluated how Tat alleles and mutants differ in cellular gene modulation of immature dendritic cells and monocyte-derived macrophages and what similarities this modulation has with that induced by interferons. The tested alleles and mutants modulated to different degrees ISG, without concomitant induction of interferons. The first exon TatSF21-72 and the minimal transactivator TatSF21-58, all modulated genes to a significantly greater extent than full-length wild type, two-exon Tat, indicating that Tat second exon is critical in reducing the innate response triggered by HIV-1 in these cells. Mutants with reduced LTR transactivation had a substantially reduced effect on host gene expression modulation than wild type TatSF2. However, the more potent LTR transactivator TatSF2A58T modulated ISG expression to a lower degree compared to TatSF2. A cellular gene modulation similar to that induced by Tat and Tat mutants in immature dendritic cells could be observed in monocyte-derived macrophages, with the most significant pathways affected by Tat being the same in both cell types. Tat expression in cells deleted of the type I IFN locus or receptor resulted in a gene modulation pattern similar to that induced in primary immature dendritic cells and monocyte-derived macrophages, excluding the involvement of type I IFNs in Tat-mediated gene modulation. ISG activation depends on Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters and a single exon Tat protein more strongly modulated the luciferase activity mediated by MAP2K3, MAP2K6, and IRF7 promoter sequences located 5' of the RNA start site than the wild type two-exon Tat, while a cysteine and lysine Tat mutants, reduced in LTR transactivation, had negligible effects on these promoters. Chemical inhibition of CDK9 or Sp1 decreased Tat activation of MAP2K3-, MAP2K6-, and IRF7-mediated luciferase transcription.

conclusionsTaken together, these data indicate that the second exon of Tat is critical to the containment of the innate response stimulated by Tat in antigen presenting cells and support a role for Tat in stimulating cellular transcription via its interaction with transcription factors present at promoters.

Indexed as

ExonsAllelesAmino Acid SequenceAntigen-Presenting CellsDendritic CellsGene Expression Regulation, ViralHIV-1HumansInterferon Regulatory Factor-7Interferon Type IMacrophagesMAP Kinase Kinase 3MAP Kinase Kinase 6Molecular Sequence DataMutationPromoter Regions, GeneticInterferon Regulatory Factor-7Interferon Type IIRF7 protein, humanMAP2K3 protein, humanMAP2K6 protein, humanMAP Kinase Kinase 3MAP Kinase Kinase 6tat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID24742347
PMCPMC4036831
OpenAlexW2170986286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.